Research Progress on the Effect and Mechanism of Probiotics in Relieving Parkinson's Disease Related Symptoms

CUI Yanru; PANG Rizhao; CEN Qiuyu; WEI Juanfang; ZHANG Anren

doi:10.13386/j.issn1002-0306.2022070268

Issue 9

May. 2023

Turn off MathJax

Article Contents

JOURNAL OF MECHANICAL ENGINEERING > 2023 > 44(9): 475-481.

CUI Yanru, PANG Rizhao, CEN Qiuyu, et al. Research Progress on the Effect and Mechanism of Probiotics in Relieving Parkinson's Disease Related Symptoms[J]. Science and Technology of Food Industry, 2023, 44(9): 475−481. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2022070268

Citation:

PDF( 759 KB)

Research Progress on the Effect and Mechanism of Probiotics in Relieving Parkinson's Disease Related Symptoms

doi: 10.13386/j.issn1002-0306.2022070268

1.
School of Health and Rehabilitation, Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China
2.
Department of Rehabilitation Medicine, the General Hospital of Western Theater Command, Chengdu 610083, China
3.
Department of Rehabilitation Medicine, Shanghai Fourth People′s Hospital Affiliated to Tongji University School of Medicine, Shanghai 200434, China

Received Date: 21 Jul 2022
Issue Publish Date: 01 May 2023

Abstract

Abstract

Parkinson's disease (PD) is a common neurological disorder of the brain. In recent years, there is increasing evidence that intestinal flora dysbiosis is closely related to the occurrence and development of PD. This suggests that intestinal microorganisms may be a new strategy for the treatment of PD. Probiotics are a group of active microorganisms that can colonize the host gut and play a beneficial role in the health of the body, and are of great significance to maintaining the intestinal microecological balance. Studies have shown that probiotics can effectively prevent and improve PD through the gut-brain axis, and the potential mechanisms of action include regulating intestinal microecology, alleviating inflammatory response and oxidative stress damage, and promoting the expression of neurotrophic factors. This article reviews the changes of intestinal flora in PD, the mechanisms of intestinal flora in the pathogenesis of PD, and the improvement effect and mechanisms of probiotics on PD-related symptoms, in order to provide a theoretical basis for probiotics to prevent and alleviate PD.
- Parkinson's disease,
- probiotics,
- gut microbiota,
- mechanism

FullText(HTML)

References(61)

References

[1]	VIJIARATNAM N, SIMUNI T, BANDMANN O, et al. Progress towards therapies for disease modification in Parkinson's disease[J]. Lancet Neurology,2021,20(7):559−572. doi: 10.1016/S1474-4422(21)00061-2
[2]	LI G, MA J, CUI S, et al. Parkinson's disease in China: A forty-year growing track of bedside work[J]. Transl Neurodegener,2019,8:22. doi: 10.1186/s40035-019-0162-z
[3]	AARSLAND D, BATZU L, HALLIDAY G M, et al. Parkinson disease-associated cognitive impairment[J]. Nat Rev Dis Primers,2021,7(1):47. doi: 10.1038/s41572-021-00280-3
[4]	TOLLESON C M, FANG J Y. Advances in the mechanisms of Parkinson's disease[J]. Discovery Medicine,2013,15(80):61−66.
[5]	ZHENG S Y, LI H X, XU R C, et al. Potential roles of gut microbiota and microbial metabolites in Parkinson's disease[J]. Ageing Research Reviews,2021,69:101347. doi: 10.1016/j.arr.2021.101347
[6]	RUTSCH A, KANTSJÖ J B, RONCHI F. The gut-brain axis: How microbiota and host inflammasome influence brain physiology and pathology[J]. Front Immunol,2020,11:604179. doi: 10.3389/fimmu.2020.604179
[7]	KIM S, KWON S H, KAM T I, et al. Transneuronal propagation of pathologic α-synuclein from the gut to the brain models Parkinson's disease[J]. Neuron,2019,103(4):627−641. doi: 10.1016/j.neuron.2019.05.035
[8]	RANI L, MONDAL A C. Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications[J]. Neuroscience Research,2021,168:100−112. doi: 10.1016/j.neures.2021.01.001
[9]	SHEN T, YUE Y, HE T, et al. The association between the gut microbiota and Parkinson's disease, a meta-analysis[J]. Front Aging Neurosci,2021,13:636545. doi: 10.3389/fnagi.2021.636545
[10]	AZAD M A K, SARKER M, LI T, et al. Probiotic species in the modulation of gut microbiota: An overview[J]. Biomed Res Int,2018,2018:9478630.
[11]	KIOUSI D E, KOUROUTZIDOU A Z, NEANIDIS K, et al. Evaluating the role of probiotics in the prevention and management of age-related diseases[J]. International Journal of Molecular Sciences,2022,23(7):3628. doi: 10.3390/ijms23073628
[12]	SNIGDHA S, HA K, TSAI P, et al. Probiotics: Potential novel therapeutics for microbiota-gut-brain axis dysfunction across gender and lifespan[J]. Pharmacol Ther,2022,231:107978. doi: 10.1016/j.pharmthera.2021.107978
[13]	MIRZAEI H, SEDIGHI S, KOUCHAKI E, et al. Probiotics and the treatment of Parkinson's disease: An update[J]. Cellular and Molecular Neurobiology,2022,42(8):2449−2457. doi: 10.1007/s10571-021-01128-w
[14]	DOROSZKIEWICZ J, GROBLEWSKA M, MROCZKO B. The role of gut microbiota and gut-brain interplay in selected diseases of the central nervous system[J]. International Journal of Molecular Sciences,2021,22(18):10028. doi: 10.3390/ijms221810028
[15]	SUN P, SU L, ZHU H, et al. Gut microbiota regulation and their implication in the development of neurodegenerative disease[J]. Microorganisms,2021,9(11):2281. doi: 10.3390/microorganisms9112281
[16]	BULLICH C, KESHAVARZIAN A, GARSSEN J, et al. Gut vibes in Parkinson's disease: The microbiota-gut-brain axis[J]. Mov Disord Clin Pract,2019,6(8):639−651. doi: 10.1002/mdc3.12840
[17]	SCHEPERJANS F, AHO V, PEREIRA P A, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype[J]. Movement Disorders,2015,30(3):350−358. doi: 10.1002/mds.26069
[18]	MINATO T, MAEDA T, FUJISAWA Y, et al. Progression of Parkinson's disease is associated with gut dysbiosis: Two-year follow-up study[J]. PLoS One,2017,12(11):e0187307. doi: 10.1371/journal.pone.0187307
[19]	HUANG Y, LIAO J, LIU X, et al. Review: The role of intestinal dysbiosis in Parkinson's disease[J]. Front Cell Infect Microbiol,2021,11:615075. doi: 10.3389/fcimb.2021.615075
[20]	ZHAO J, BI W, XIAO S, et al. Neuroinflammation induced by lipopolysaccharide causes cognitive impairment in mice[J]. Sci Rep,2019,9(1):5790. doi: 10.1038/s41598-019-42286-8
[21]	WALLEN Z D, APPAH M, DEAN M N, et al. Characterizing dysbiosis of gut microbiome in PD: Evidence for overabundance of opportunistic pathogens[J]. NPJ Parkinsons Dis,2020,6:11. doi: 10.1038/s41531-020-0112-6
[22]	SAMPSON T R, DEBELIUS J W, THRON T, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease[J]. Cell,2016,167(6):1469−1480. doi: 10.1016/j.cell.2016.11.018
[23]	SUN M F, ZHU Y L, ZHOU Z L, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway[J]. Brain Behav Immun,2018,70:48−60. doi: 10.1016/j.bbi.2018.02.005
[24]	ZHAO Z, NING J, BAO X Q, et al. Fecal microbiota transplantation protects rotenone-induced Parkinson's disease mice via suppressing inflammation mediated by the lipopolysaccharide-TLR4 signaling pathway through the microbiota-gut-brain axis[J]. Microbiome,2021,9(1):226. doi: 10.1186/s40168-021-01107-9
[25]	KOUTZOUMIS D N, VERGARA M, PINO J, et al. Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease[J]. Experimental Neurology,2020,325:113159. doi: 10.1016/j.expneurol.2019.113159
[26]	KANG Y, KANG X, ZHANG H, et al. Gut microbiota and Parkinson's disease: Implications for faecal microbiota transplantation therapy [J]. ASN Neuro, 2021, 13: 17590914211016217.
[27]	YIU J H, DORWEILER B, WOO C W. Interaction between gut microbiota and toll-like receptor: From immunity to metabolism[J]. Journal of Molecular Medicine (Berlin),2017,95(1):13−20. doi: 10.1007/s00109-016-1474-4
[28]	SUN M F, SHEN Y Q. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's disease[J]. Ageing Research Reviews,2018,45:53−61. doi: 10.1016/j.arr.2018.04.004
[29]	PIETRUCCI D, CERRONI R, UNIDA V, et al. Dysbiosis of gut microbiota in a selected population of Parkinson's patients[J]. Parkinsonism & Related Disorders,2019,65:124−130.
[30]	AHO V T E, PEREIRA P A B, VOUTILAINEN S, et al. Gut microbiota in Parkinson's disease: Temporal stability and relations to disease progression[J]. EBioMedicine,2019,44:691−707. doi: 10.1016/j.ebiom.2019.05.064
[31]	LIN C H, CHEN C C, CHIANG H L, et al. Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson's disease[J]. Journal of Neuroinflammation,2019,16(1):129. doi: 10.1186/s12974-019-1528-y
[32]	CIRSTEA M S, YU A C, GOLZ E, et al. Microbiota composition and metabolism are associated with gut function in Parkinson's disease[J]. Movement Disorders,2020,35(7):1208−1217. doi: 10.1002/mds.28052
[33]	VASCELLARI S, PALMAS V, MELIS M, et al. Gut microbiota and metabolome alterations associated with Parkinson's disease[J]. mSystems,2020,5(5):e00561−620.
[34]	BARICHELLA M, SEVERGNINI M, CILIA R, et al. Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism[J]. Movement Disorders,2019,34(3):396−405. doi: 10.1002/mds.27581
[35]	UNGER M M, SPIEGEL J, DILLMANN K U, et al. Short chain fatty acids and gut microbiota differ between patients with Parkinson's disease and age-matched controls[J]. Parkinsonism & Related Disorders,2016,32:66−72.
[36]	TAN A H, HOR J W, CHONG C W, et al. Probiotics for Parkinson's disease: Current evidence and future directions[J]. JGH Open,2021,5(4):414−419. doi: 10.1002/jgh3.12450
[37]	MUKHERJEE A, BISWAS A, DAS S K. Gut dysfunction in Parkinson's disease[J]. World Journal of Gastroenterology,2016,22(25):5742−5752. doi: 10.3748/wjg.v22.i25.5742
[38]	TSAO S P, NURRAHMA B A, KUMAR R, et al. Probiotic enhancement of antioxidant capacity and alterations of gut microbiota composition in 6-hydroxydopamin-induced Parkinson's disease rats[J]. Antioxidants (Basel),2021,10(11):1823. doi: 10.3390/antiox10111823
[39]	IBRAHIM A, ALI R A R, MANAF M R A, et al. Multi-strain probiotics (Hexbio) containing MCP BCMC strains improved constipation and gut motility in Parkinson's disease: A randomised controlled trial[J]. PLoS One,2020,15(12):e0244680. doi: 10.1371/journal.pone.0244680
[40]	TAN A H, LIM S Y, CHONG K K, et al. Probiotics for constipation in Parkinson disease: A randomized placebo-controlled study[J]. Neurology,2021,96(5):e772−e782.
[41]	BARICHELLA M, PACCHETTI C, BOLLIRI C, et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT[J]. Neurology,2016,87(12):1274−1280. doi: 10.1212/WNL.0000000000003127
[42]	GEORGESCU D, ANCUSA O E, GEORGESCU L A, et al. Nonmotor gastrointestinal disorders in older patients with Parkinson's disease: Is there hope?[J]. Clinical Interventions in Aging,2016,11:1601−1608. doi: 10.2147/CIA.S106284
[43]	TAMTAJI O R, TAGHIZADEH M, DANESHVAR KAKHAKI R, et al. Clinical and metabolic response to probiotic administration in people with Parkinson's disease: A randomized, double-blind, placebo-controlled trial[J]. Clinical Nutrition,2019,38(3):1031−1035. doi: 10.1016/j.clnu.2018.05.018
[44]	HSIEH T H, KUO C W, HSIEH K H, et al. Probiotics alleviate the progressive deterioration of motor functions in a mouse model of Parkinson's disease[J]. Brain Sci,2020,10(4):206. doi: 10.3390/brainsci10040206
[45]	ISHII T, FURUOKA H, KAYA M, et al. Oral administration of probiotic bifidobacterium breve improves facilitation of hippocampal memory extinction via restoration of aberrant higher induction of neuropsin in an MPTP-induced mouse model of Parkinson's disease[J]. Biomedicines,2021,9(2):167. doi: 10.3390/biomedicines9020167
[46]	ALIPOUR NOSRANI E, TAMTAJI O R, ALIBOLANDI Z, et al. Neuroprotective effects of probiotics bacteria on animal model of Parkinson's disease induced by 6-hydroxydopamine: A behavioral, biochemical, and histological study[J]. J Immunoassay Immunochem,2021,42(2):106−120. doi: 10.1080/15321819.2020.1833917
[47]	VAN ZYL W F, DEANE S M, DICKS L M T. Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria[J]. Gut Microbes,2020,12(1):1831339. doi: 10.1080/19490976.2020.1831339
[48]	WANG L, ZHAO Z, ZHAO L, et al. Lactobacillus plantarum DP189 reduces α-SYN aggravation in MPTP-induced Parkinson's disease mice via regulating oxidative damage, inflammation, and gut microbiota disorder[J]. Journal of Agricultural and Food Chemistry,2022,70(4):1163−1173. doi: 10.1021/acs.jafc.1c07711
[49]	MAROGIANNI C, SOKRATOUS M, DARDIOTIS E, et al. Neurodegeneration and inflammation-an interesting interplay in Parkinson's disease[J]. International Journal of Molecular Sciences,2020,21(22):8421. doi: 10.3390/ijms21228421
[50]	BORZABADI S, ORYAN S, EIDI A, et al. The effects of probiotic supplementation on gene expression related to inflammation, insulin and lipid in patients with Parkinson's disease: A randomized, double-blind, placebocontrolled trial[J]. Arch Iran Med,2018,21(7):289−295.
[51]	PEREZ VISÑUK D, SAVOY DE GIORI G, LEBLANC J G, et al. Neuroprotective effects associated with immune modulation by selected lactic acid bacteria in a Parkinson's disease model[J]. Nutrition,2020,79-80:110995. doi: 10.1016/j.nut.2020.110995
[52]	CASTELLI V, D'ANGELO M, LOMBARDI F, et al. Effects of the probiotic formulation SLAB51 in in vitro and in vivo Parkinson's disease models[J]. Aging,2020,12(5):4641−4659. doi: 10.18632/aging.102927
[53]	MAGISTRELLI L, AMORUSO A, MOGNA L, et al. Probiotics may have beneficial effects in Parkinson's disease: In vitro evidence[J]. Front Immunol,2019,10:969. doi: 10.3389/fimmu.2019.00969
[54]	HOU Y, LI X, LIU C, et al. Neuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease[J]. Experimental Gerontology,2021,150:111376. doi: 10.1016/j.exger.2021.111376
[55]	GUO J D, ZHAO X, LI Y, et al. Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review)[J]. International Journal of Molecular Medicine,2018,41(4):1817−1825.
[56]	NURRAHMA B A, TSAO S P, WU C H, et al. Probiotic supplementation facilitates recovery of 6-OHDA-induced motor deficit via improving mitochondrial function and energy metabolism[J]. Front Aging Neurosci,2021,13:668775. doi: 10.3389/fnagi.2021.668775
[57]	NASROLAHI A, MAHMOUDI J, AKBARZADEH A, et al. Neurotrophic factors hold promise for the future of Parkinson's disease treatment: Is there a light at the end of the tunnel?[J]. Reviews in the Neurosciences,2018,29(5):475−489. doi: 10.1515/revneuro-2017-0040
[58]	PALASZ E, WYSOCKA A, GASIOROWSKA A, et al. BDNF as a promising therapeutic agent in Parkinson's disease[J]. International Journal of Molecular Sciences,2020,21(3):1170. doi: 10.3390/ijms21031170
[59]	WONG C E D, HUA K, MONIS S, et al. Gdnf affects early diencephalic dopaminergic neuron development through regulation of differentiation-associated transcription factors in zebrafish[J]. Journal of Neurochemistry,2021,156(4):481−498. doi: 10.1111/jnc.15108
[60]	LIAO J F, CHENG Y F, YOU S T, et al. Lactobacillus plantarum PS128 alleviates neurodegenerative progression in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced mouse models of Parkinson's disease[J]. Brain Behav Immun,2020,90:26−46. doi: 10.1016/j.bbi.2020.07.036
[61]	SRIVASTAV S, NEUPANE S, BHURTEL S, et al. Probiotics mixture increases butyrate, and subsequently rescues the nigral dopaminergic neurons from MPTP and rotenone-induced neurotoxicity[J]. Journal of Nutritional Biochemistry,2019,69:73−86. doi: 10.1016/j.jnutbio.2019.03.021